Roche Holding | ROG - Selling And Administration Expenses


Roche Holding reported CHF7.28B in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Alcon AG USD 882M 19M Mar/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Orion EUR 91.9M 18.8M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Philips EUR 1.18B 121M Mar/2026
Recordati EUR 192.76M 5.52M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025